533 An open label Phase IA/IB study for safety, pharmacokinetics (PK), and efficacy of ONC 392 as a single agent and in combination with Pembrolizumab in advanced solid tumors
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |